Advanz Partners With Eisai For Zonisamide
In Europe, The Middle East, Russia And Australia
Advanz has entered into an agreement with Eisai to acquire rights to its Zonegran zonisamide brand in Europe, the Middle East, Russia and Australia. Advanz said the move was “in keeping with our strategic growth plans” after the company was recently acquired by Nordic Capital in an $846m deal.
You may also be interested in...
Plus deals involving Zai Lab/MacroGenics, Ono/Rafael Pharmaceuticals, Beijing Podconley/Norgine, Nuance/Verona and BeiGene/Shoreline.
Nordic Capital has completed its takeover of Advanz Pharma, three years after the company’s transformation from its former identity of Concordia. The company is planning “considerable investment” following the deal.
Advanz added $5.5m of revenue from its recently acquired alprostadil products and $3.3m from Correvio in the second quarter of 2020. After seeking approval for seven medicines during the second quarter alone, the company plans to launch another 17 products in 2020.